62 results about "Human myocardium" patented technology

The present invention provides a non-human animal model of myocardial infarction, which can be created by a less invasive method, shows an extremely low mortality during and after surgical induction of myocardial infarction, ensures the blood reflow after necrosis of cardiac muscles caused by blocking blood flow, and therefore, is usable in topical therapy for myocardial infarction and studies on regenerative medicine. The present invention also provides a method for creating the non-human animal model comprising administering a temporary embolic agent to a branch blood vessel of a heart coronary artery to block blood flow in the branch blood vessel; and after a definite period of time after said vascular branch blockage, administering a temporary embolic agent to the target coronary artery which is intended to induce myocardial infarction to block blood flow in the target coronary artery.

The present invention provides a new method for producing Engineered Heart Muscle (EHM) under chemically fully defined conditions and compounds all compatible with GMP regulations. The resulting human myocardium generates force and shows typical heart muscle properties.

The present invention discloses human cardiac troponin I hybridoma cell line 7H4 and a monoclonal antibody and application. The hybridoma cell line 7H4 is deposited with the China Center for Type Culture Collection (CCTCC) on August 23, 2017 under accession number CCTCC NO: C2017121. The monoclonal antibody 7H4 secreted by the hybridoma cell line 7H4 is a high-affinity and high-specificity cTnI monoclonal antibody, can combines cTnI in three forms comprising free cTnI, dimeric complex cTnI-C and trimeric complex cTnI-T-C, can be used to detect the content of the cTnI in serum, and lays a foundation for development of a kit for rapid detection of myocardial infarction.

The invention discloses a method for constructing a human myocardial cell apoptosis model. The inventor accidentally finds that after angiotensin II with a certain concentration is used for treating hiPSC-CM for a certain time, the apoptosis of hiPSC-CM can be effectively induced. According to some examples of the invention, the angiotensin II is used for inducing the apoptosis of human myocardialcells, and the myocardial cell apoptosis model closer to the human body is constructed, so that a powerful tool and method are provided for subsequent pharmacological experiments.

The invention discloses a triple detection chromatography test strip for human cardiac troponin I (cTnI), a human growth differentiation factor 15 (GDF-15) and a human D dimer (DD) and an application thereof. The test strip comprises a bottom plate, a sample adding pad, a combination pad, a detection pad and a water absorption pad, wherein the sample adding pad, the combination pad, the detection pad and the water absorption pad are sequentially arranged on the bottom plate. Immunofluorescent microspheres for marking mouse anti-GDF-15 monoclonal antibodies, cTnI monoclonal antibodies and DD monoclonal antibodies and immunofluorescent microspheres for marking rabbit IgG are wrapped on the combination pad, monoclonal capture antibodies of mouse anti-GDF-15 monoclonal antibodies, cTnI monoclonal antibodies and DD monoclonal antibodies are wrapped on a detection line, and goat anti-rabbit IgG polyclonal antibodies are wrapped on a quality inspection line. The preparation method is improved so that the sensitivity and the specificity of the test strip for detecting three markers by adopting a fluorescent quantitative method are improved, and a new technical means is provided for detection of myocardial functions.

The present invention belongs to the biotechnological field and relates to a human myocardial protection gene heat shock transcription factor (HSF1) and a sieving method and a purpose thereof. The present invention adopts the method of ''death trap'' that the gene which resists myocardial cell death is sieved from human cardiac gene, and the human myocardial protection gene heat shock transcription factor 1 is cloned from the obtained gene. The result of transfection cell and animal experiment shows that the obtained human myocardial protection gene has the function of resisting cell death and also has the function of resisting ischemia, protecting myocardial cell and preventing and remedying the heart failure occurrence and development inside the heart of a living organism. The present invention can prepare for the medicine for remedying the ischemic heart disease and preventing the cardiac insufficiency and provides a novel target gene for the further function research and the gene engineering medicine development, which has important meaning for the early prevention and treatment of the heart failure and the research and the development of the related medicines and measures.

The invention relates to a novel isolated binding protein containing a cTnI antigen binding domain, and researches of the preparation, the applications and the like of the binding protein. The bindingprotein is high in activity, has high affinity with human cTnI protein, and can be widely applied to the field of cTnI protein detection.

The invention belongs to the technical field of medicines, and discloses an application of an andrographolide derivative in the preparation of medicaments for preventing and treating various fibrosis.The invention relates to an application of 14-deoxy-11, 12-dehydrogenation-7, 8-ene-andrographolide and a 15-subunit substituted derivative. Experiments prove that the compound obviously inhibits themigration and activation of hepatic stellate cells; significantly inhibits TGF-beta1 induced mesenchymal transformation of human alveolar type II epithelial cells A549; significantly inhibits TGFbeta1 induced HK-2 mesenchymal transformation of human renal cortical proximal tubular epithelial cells; inhibits the migration of HCFB in primary human cardiac fibroblasts induced by angiotensin II (AngII). In a model of common bile duct ligation in mice, a model of pulmonary fibrosis induced by silica in mice and a model of unilateral ureteral ligation in mice, the compound shows good anti-fibrosisactivity in vivo. The compound is used as an active ingredient for preparing the anti-fibrosis medicament, has high efficiency and low toxicity, and has a good prospect of developing various anti-fibrosis medicaments.

The invention relates to a novel isolated binding protein containing a cTnI antigen binding domain, and researches of the preparation, the applications and the like of the binding protein. The bindingprotein is high in activity, has high affinity with human cTnI protein, and can be widely applied to the field of cTnI protein detection.

The invention relates to a recombinant antibody of an anti-human cardiac troponin I, particularly to a novel isolated binding protein containing a cTnI antigen binding domain, and researches of the preparation, the applications and the like of the binding protein. The binding protein is high in activity, has high affinity with human cTnI protein, and can be widely applied to the field of cTnI protein detection.

The invention relates to a novel isolated binding protein containing a cTnI antigen binding domain, and researches of the preparation, the applications and the like of the binding protein. The bindingprotein is high in activity, has high affinity with human cTnI protein, and can be widely applied to the field of cTnI protein detection.